一项关于替代TrkA拼接的研究确定TrkAIII是PitNET进展中的一个新的潜在可针对的参与者
Maddalena Sbaffone1, Marie-Lise Jaffrain-Rea1,2, Lucia Cappabianca1
1Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Via Vetoio, 67100 L'Aquila, Italy.
Biology
|March 27, 2024
概括
TrkAIII的替代拼接在垂体神经内分泌瘤 (PitNETs) 中很常见,特别是在侵略性,侵入性类型中. 这种拼接可能会激活TrkAIII,这表明它是抗性PitNETs的新治疗点.
科学领域:
- 内分泌学 在内分泌学.
- 分子生物学分子生物学
- 在瘤学瘤学.
背景情况:
- 下垂体神经内分泌瘤 (PitNETs) 有一个侵略性的子集,需要新的治疗点.
- 替代拼接是PitNETs的一个致癌途径.
- 神经营蛋白受体TrkA,具有瘤性TrkAIII拼接,在PitNETs中表达.
研究的目的:
- 调查TrkAIII剪接在PitNET病原和进展中的作用.
- 确定TrkAIII拼接是否代表了PitNETs中的潜在的致癌参与者.
主要方法:
- 在53个PitNET中通过RT-PCR进行评估TrkAIII剪接.
- 通过共聚焦性免疫光学评估TrkA异型表达和激活.
- 与表达HIF1α,HIF2α,SF3B1,SRSF2,U2AF1,JCPyV大T抗原,Xbp1拼接和SF3B1突变的拼接进行了比较.
主要成果:
- 在所有侵袭性和大多数非侵袭性PitNET中检测到TrkAIII拼接,在侵袭性病例中显著增加.
- 在侵袭性PIT1PitNET和SF1和TPIT系系中,TrkAIII拼接更高.
- 在具有TrkAIIImRNA的PitNET中观察到TrkAIII激活;侵入性Pit1PitNET显示HIF2α表达增加.
结论:
- 在PitNET中,特别是侵入性亚型中,TrkAIII拼接很普遍,可能导致TrkAIII激活.
- 低氧可能参与PitNET中的TrkAIII拼接.
- TrkAIII代表了耐火性PitNETs的一个潜在的新疗法标.
相关概念视频
Enzyme-linked Receptors
78.3K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
78.3K
PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K


